Trade Summary
On Oct 21, 2026, Sheena Jonathan, Insider, sold $1.3M of Natera, Inc. (NTRA) across 8 transactions. The filing covers Common Stock and reflects net selling of $1.3M. Reported prices ranged from $406.50 to $416.67. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Natera, Inc.
- Ticker Symbol
- NTRA
- CIK
- 0001604821
Insider Information
- Name
- Sheena Jonathan
- Role
- Insider
- Location
- AUSTIN, TX
Filing Details
- Filing Date
- Oct 23, 2026
- Transaction Date
- Oct 21, 2026
- Accession Number
- 0001646649-26-000035
- Form Type
- 4
- Net Trading Amount
- -$1.3M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Oct 21, 2026 | Common Stock | 200 | $406.50 | Sale | $81.3K |
| Oct 21, 2026 | Common Stock | 962 | $408.26 | Sale | $392.7K |
| Oct 21, 2026 | Common Stock | 627 | $409.89 | Sale | $257.0K |
| Oct 21, 2026 | Common Stock | 605 | $411.32 | Sale | $248.8K |
| Oct 21, 2026 | Common Stock | 211 | $412.20 | Sale | $87.0K |
| Oct 21, 2026 | Common Stock | 125 | $413.05 | Sale | $51.6K |
| Oct 21, 2026 | Common Stock | 255 | $415.67 | Sale | $106.0K |
| Oct 21, 2026 | Common Stock | 165 | $416.67 | Sale | $68.8K |
Want live alerts when Sheena Jonathan trades again?
Download Insider Trades to track NTRA, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- (F2)The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $408.00 to $408.96 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (F3)The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $409.22 to $410.03 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (F4)The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $410.91 to $411.64 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (F5)The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $412.00 to $412.21 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (F6)The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $413.00 to $413.09 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (F7)The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $415.35 to $416.24 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (F8)The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $416.36 to $416.81 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (F9)Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.